Brodalumab

From WikiMD.org
Jump to navigation Jump to search

Brodalumab

Brodalumab (pronounced broh-dah-LOO-mab) is a human monoclonal antibody used for the treatment of psoriasis, a chronic skin condition. It is marketed under the brand name Siliq in the United States and Kyntheum in Europe.

Etymology

The name "Brodalumab" is derived from the combination of the words "broad" and "lumab", where "lumab" is a common suffix for monoclonal antibodies. The "broad" part of the name is likely a reference to the broad spectrum of inflammatory conditions that the drug can potentially treat.

Mechanism of Action

Brodalumab works by binding to the interleukin-17 receptor A (IL-17RA), a protein that plays a key role in the development of psoriasis. By blocking this receptor, Brodalumab can reduce the inflammation and other symptoms associated with psoriasis.

Related Terms

  • Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
  • Psoriasis: A chronic skin condition that causes cells to build up rapidly on the surface of the skin.
  • Interleukin-17 receptor A: A protein that plays a key role in the development of psoriasis.

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski